Platelet-Derived Microparticles (MPs) and Thrombin Generation Velocity in Deep Vein Thrombosis (DVT): Results of a Case–Control Study

References

• Writing Group M, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Brunson A, White R, et al. The epidemiology of cancer-associated venous thromboembolism: an update. Semin Thromb Hemost. 2019;45(4):321–325. doi:10.1055/s-0039-1688494
   PubMed Web of Science ®Google Scholar
• Jara-Palomares L, van Es N, Praena-Fernandez JM, et al. Relationship between type of unprovoked venous thromboembolism and cancer location: an individual patient data meta-analysis. Thromb Res. 2019;176:79–84. doi:10.1016/j.thromres.2019.02.011
   PubMed Web of Science ®Google Scholar
• Figueroa A, Alfonso A, Lopez-Picazo J, et al. Insights into venous thromboembolism prevention in hospitalized cancer patients: lessons from a prospective study. PLoS One. 2018;13(8):e0200220. doi:10.1371/journal.pone.0200220
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Candeloro M, Rutjes AWS, et al. Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. J Thromb Haemost. 2018;16(7):1336–1346. doi:10.1111/jth.14149
   PubMed Web of Science ®Google Scholar
• Simioni P, Tormene D, Spiezia L, et al. Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost. 2006;32:700. doi:10.1055/s-2006-951298
   PubMed Web of Science ®Google Scholar
• Campello E, Spiezia L, Radu CM, et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without thromboembolism. Thromb Res. 2011;127:437. doi:10.1016/j.thromres.2011.01.002
   Web of Science ®Google Scholar
• Beccattini C, Agnelli G, Schenone A, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959. doi:10.1056/NEJMoa1114238
   PubMed Web of Science ®Google Scholar
• Brighton TA, Eikelboom JW, Mann K, et al. The ASPIRE investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979–1987. doi:10.1056/NEJMoa1210384
   PubMed Web of Science ®Google Scholar
• Rautou P, Mackman N. Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol. 2013;6(1):91–101. doi:10.1586/ehm.12.74
   PubMed Web of Science ®Google Scholar
• Pigault C, Folleniuswund A, Schmutz M, et al. Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol. 1994;236:199. doi:10.1006/jmbi.1994.1129
   PubMed Web of Science ®Google Scholar
• Fricke A, Ullrich P, Cimniak AFV, et al. Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism. BMC Cancer. 2017;17:527. doi:10.1186/s12885-017-3515-y
   PubMed Web of Science ®Google Scholar
• Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980;104I:10. doi:10.1016/0003-2697(80)90269-9
   Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.026
   PubMed Web of Science ®Google Scholar
• Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347:f5133. doi:10.1136/bmj.f5133
   PubMed Web of Science ®Google Scholar
• Morel O, Toti F, Hugel B. Procoagulant microparticles: disrupting the vascular equation? Arterioscler Thromb Vasc Biol. 2006;26(12):2594–2604. doi:10.1161/01.ATV.0000246775.14471.26
   PubMed Web of Science ®Google Scholar
• Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohaemorrhagic Escherichia coli-induced haemolytic uremic syndrome. Blood. 2011;117(20):5503–5513. doi:10.1182/blood-2010-09-309161
   PubMed Web of Science ®Google Scholar
• Nomura S, Nakamura T, Cone J, et al. Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation. Cytometry. 2000;40(3):173–181. doi:10.1002/1097-0320(20000701)40:3<173::AID-CYTO1>3.0.CO;2-L
   PubMedGoogle Scholar
• Prasad KS, Andre P, He M, et al. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signalling. Proc Natl Acad Sci U S A. 2003;100(21):12367–12371.
   PubMed Web of Science ®Google Scholar
• Tschuor C, Asmis LM, Lenzlinger PM, et al. In vitro norepinephrine significantly activates isolated platelets from healthy volunteers and critically ill patients following severe traumatic brain injury. Crit Care. 2008;12(3):R80. doi:10.1186/cc6931
   PubMed Web of Science ®Google Scholar
• Camera M, Brambilla M, Toschi V, et al. Tissue factor expression on platelets is a dynamic event. Blood. 2010;116:5076–5077. doi:10.1182/blood-2010-09-307306
   PubMed Web of Science ®Google Scholar
• Escolar G, Lopez-Vilchez I, Diaz-Ricart M, et al. Internalization of tissue factor by platelets. Thromb Res. 2008;122(Suppl. 1):S37–S41. doi:10.1016/S0049-3848(08)70017-3
   PubMedGoogle Scholar
• Lopez-Vilchez I, Escolar G, Diaz-Ricart M, et al. Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thromb Haemost. 2007;97(2):202–211. doi:10.1160/TH06-04-0216
   PubMed Web of Science ®Google Scholar
• Lim W, Le Gal G, Bates SM, et al. American Society of Haematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2:3226–3325.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54(3):1901647.
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomized trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308:235. doi:10.1136/bmj.308.6923.235
   PubMed Web of Science ®Google Scholar
• Korte W, Jovic R, Hollenstein M, et al. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin. Hamostaseologie. 2010;30:212. doi:10.1055/s-0037-1619058
   PubMed Web of Science ®Google Scholar
• Ferrante M, Fiore M, Oliveri Conti G, et al. Transition and heavy metals compared to oxidative parameter balance in patients with deep vein thrombosis: a case-control study. Mol Med Rep. 2017;15:3438. doi:10.3892/mmr.2017.6394
   PubMed Web of Science ®Google Scholar
• Balasubramanian K, Bevers EM, Willems GM, et al. Binding of Annexin V to membrane products of lipid peroxidation. Biochemistry. 2001;40:8672. doi:10.1021/bi010841y
   PubMed Web of Science ®Google Scholar
• Chirinos JA, Heresi GA, Velasquez H, et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol. 2005;45:1467. doi:10.1016/j.jacc.2004.12.075
   PubMed Web of Science ®Google Scholar
• Thaler J, Koppensteiner R, Pabinger I, et al. Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. Thromb Res. 2014;134:1093. doi:10.1016/j.thromres.2014.07.041
   PubMed Web of Science ®Google Scholar
• Dignat GF, Camoin JL, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of antiphospholipid syndrome. Thromb Haemost. 2004;91:667.
   PubMed Web of Science ®Google Scholar
• Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122:2011. doi:10.1182/blood-2013-04-460147
   PubMed Web of Science ®Google Scholar
• Mege D, Aubert M, Lacroix R, et al. Involvement of platelets in cancers. Semin Thromb Hemost. 2019;45(6):569–575. doi:10.1055/s-0039-1693475
   PubMed Web of Science ®Google Scholar
• Mahajan A, Wun T. Biomarkers of cancer-associated thromboembolism. Cancer Treat Res. 2019;179:69–85.
   PubMedGoogle Scholar
• Falanga A, Schieppati F, Russo L. Pathophysiology 1. Mechanisms of thrombosis in cancer patients. Cancer Treat Res. 2019;179:11–36.
   PubMedGoogle Scholar
• Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62–69. doi:10.1053/j.seminhematol.2007.02.004
   PubMed Web of Science ®Google Scholar